期刊文献+

美托洛尔合用依那普利对新发青年高血压的疗效

Evaluation the effect of metoprolol tartrate tablets combine enalapril maleate tablets on the treatment of newly-onset young essential hypertension
下载PDF
导出
摘要 目的 利用动态血压检测评价酒石酸美托洛尔合用马来酸依那普利治疗青年新发高血压的疗效.方法 78例入选患者服用酒石酸美托洛尔12.5 mg,每日2次,马来酸依那普利5 mg,每日1次,并逐渐加量至诊室血压达标或最大量美托洛尔150 mg/d、马来酸依那普利20 mg/d,服用3周.治疗前、后进行动态血压检测.结果 治疗前24 h平均SBP为(162.4±9.8)mm Hg,DBP为(94.2±7.5)mm Hg,治疗后SBP为(128.3±5.8)mm Hg,DBP为(73.2±6.1)mm Hg,均显著降低(P<0.01),夜间血压下降率明显增加(P<0.01),总有效率97.43%.结论 对新发青年高血压,酒石酸美托洛尔联合马来酸依那普利能达到24 h平稳降压. Objective Evalution the effect of metoprolol tartrate tablets combine enalapril maleate tablets on the treatment of newly-onset young essential hypertension by using ABPM technology. Methods 778 selected patients were given with metoprolol tartrate of 12.5 mg twice a day and enalapril maleate of 5 mg once a day and the dosage was gradually increased until reaching the target office blood pressure or metoprolol in the maximum dosage of 150 mg and Enalapril maleate of 20 mg once a day. Medication lasted for 3 weeks. Ambulatory blood pressure test was taken before and after treatment. Results The 24 h meanbloodpressure before treatment: SBP ( 162.4±9.8)mm Hg, DBP(94.2±7.5)mm Hg, after treatment:SBP(128.3±5.8)mm Hg, DBP (73.2±6.1)mm Hg. 24 h Ambulatory blood pressure was obviously declined after treatment (P〈0.01). Nighttime blood pressure decrease rate significantly increased (P〈0.01). The total effective rate was 97.43%. Conclusion Steady blood pressure decline for 24 hours can be achieved by medication of metoprolol tartrate combined with enalapril maleate for young patients who has newly onset essential hypertension.
出处 《中国心血管病研究》 CAS 2011年第12期917-918,共2页 Chinese Journal of Cardiovascular Research
关键词 高血压 美托洛尔 依那普利 Hypertension Metoprolol Enalapril
  • 相关文献

参考文献5

二级参考文献32

  • 1吕飒美,雷琳娜,史丽萍.老年高血压患者脉压大小与靶器官损害的关系[J].中国老年学杂志,2005,25(10):1230-1231. 被引量:8
  • 2华琦.解读《中国高血压防治指南》(2005年修订版)(一) 高血压诊疗新进展[J].中国心血管病研究,2006,4(2):85-88. 被引量:156
  • 3[1]Palaltini P, Julius S. Review article: Heart rate and the cardiovascular risk[J]. J Hypertens, 1997, 15: 3 - 17
  • 4[4]Plaltini P, Julius S. Review article:Association of tachycardia with morbidity and mortality: pathophysiological consideration [J]. J Hum Hypertens, 1997, 11 (suppl 1):19-27
  • 5[6]Kekalainen P, Sarlund H, Laakso M. Long- term association of cardiovascular risk factors with impaired insulin secretion and insulin resistance [J]. Metabolism,2000, 49(10): 1247 - 1254
  • 6[14]Domanski M,Mitchell G,Pfeifer M,et al.Pulse pressure and cardiovascular disease-related mortality:follow-up study of the multiple risk factor intervention trial (MRFIT).JAMA,2002,287:2677-2683.
  • 7[15]Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction:interim report from the Chinese cardiac study (CCS-1).Lancet,1995,18,345:686-687.
  • 8[16]Maschio G,Alberti D,Locatelli F,et al.Angiotensin converting enzyme inhibitors and kidney protection:the AIPRI trial.The ACE inhibition in progressive renal insufficiency (AIPRI)study group.Cardiovasc Pharmacol,1999,33:S16-S20.
  • 9[17]Parving HH.Hypertension and diabetes:the scope of the problem.Blood Press Suppl,2001(Suppl 2):S25-S31.
  • 10[18]Lewis EJ,Hunsicker LG,Clarke WR,et al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J MED,2001,345:851-860.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部